www.fdanews.com/articles/123428-lilly-sues-app-pharma-over-gemzar-patent-infringement
Lilly Sues APP Pharma Over Gemzar Patent Infringement
January 7, 2010
Eli Lilly is suing
APP Pharmaceuticals over its Gemzar ANDA, alleging it infringes a patent for the cancer treatment. APP’s ANDA says four claims
of Lilly’s ’826 patent are invalid and three claims would not be infringed due to obviousness-type double patenting, according to Lilly’s
suit filed recently in the U.S. District Court for the Southern District of Indiana. The drug is approved to treat nonsmall cell lung cancer and cancers
of the pancreas, breast and ovaries.
Drug Industry Daily
Drug Industry Daily